Two Of The Cyclos Share At Least Three Ring Members Or A Ring Member Is Shared By Three Of The Cyclos (e.g., Bridged, Peri-fused, Etc., Toxiferin) Patents (Class 540/472)
  • Patent number: 9711201
    Abstract: Artificial ices enable the study of geometrical frustration by design and through direct observation. It has, however, proven difficult to achieve tailored long-range ordering of their diverse configurations, limiting both fundamental and applied research directions. An artificial spin structure design is described that produces a magnetic charge ice with tunable long-range ordering of eight different configurations. A technique is also developed to precisely manipulate the local magnetic charge states and demonstrate write-read-erase multi-functionality at room temperature. This globally reconfigurable and locally writable magnetic charge ice provides a setting for designing magnetic monopole defects, tailoring magnetics and controlling the properties of other two-dimensional materials.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: July 18, 2017
    Assignees: UCHICAGO ARGONNE, LLC, BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY
    Inventors: Yong-Lei Wang, Zhi-Li Xiao, Wai-Kwong Kwok
  • Patent number: 9701684
    Abstract: This invention relates to fluorinating agents and, more particularly, to chiral non-racemic fluorinating agents useful for enantioselective fluorination, as well as to their synthesis and use and other subject matter. The fluorinating agents are based on a substituted 1,4-diazabicyclo[2.2.2]octane (DABCO) skeleton and provide electrophillic fluorine enantioselectively.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: July 11, 2017
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Veronique Gouverneur, Graham Sandford
  • Patent number: 9365532
    Abstract: The present invention relates to the synthesis, composition and use of novel moieties formed by reacting a transimination nucleophilic catalyst, molecular or polymeric, with carbonyl-containing therapeutic or cosmetic moieties. The resultant Schiff base product is highly reactive towards transimination with a biological amine. The catalyst and carbonyl-containing moiety can be molecular or polymeric, and the resultant chemical and physical properties of the Schiff base products can be engineered by appropriate selection of said catalyst. The present invention also relates to the synthesis, composition and use of novel moieties that are used as actives in sunless tanning preparations. The present invention also relates to the use of transimination nucleophilic catalysts to increase the rate at which a carbonyl-containing moiety reacts with a biological amine.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: June 14, 2016
    Assignee: Nanometics, LLC.
    Inventor: Steven Isaacman
  • Patent number: 9142471
    Abstract: A doped, passivated graphene nanomesh includes a graphene nanomesh, a plurality of nanoholes formed in a graphene sheet, and a plurality of carbon atoms which are formed adjacent to the plurality of nanoholes; a passivating element bonded to the plurality of carbon atoms; and a dopant bonded to the passivating element, the dopant comprising one of an electron-donating element for making the graphene nanomesh an n-doped graphene nanomesh, and an electron-accepting element for making the graphene nanomesh a p-doped graphene nanomesh.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: September 22, 2015
    Assignees: International Business Machines Incorporated, Egypt Nanotechnology Center
    Inventors: Ahmed Abou-Kandil, Ahmed Maarouf, Glenn John Martyna, Hisham Mohamed, Dennis M. Newns
  • Patent number: 9018318
    Abstract: A macrocycle based on ?-diketimines, a process for preparing the inventive macrocycle, an uncharged macrocyclic dimetallic complex based on the inventive macrocycle, and a process for preparing the uncharged macrocyclic dimetallic complex, the use of the uncharged macrocyclic dimetallic complex as a polymerization catalyst in the polymerization of carbon dioxide with one or more epoxides, a process for preparing polycarbonates by reacting carbon dioxide with one or more epoxides in the presence of the inventive uncharged macrocyclic dimetallic complex, and a polycarbonate prepared by the process according to the invention.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: April 28, 2015
    Assignee: BASF SE Corporation
    Inventors: Peter Deglmann, Anna Katharina Brym, Bernhard Rieger, Maximilian Lehenmeier, Stephan Klaus
  • Publication number: 20150112058
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J.P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • Publication number: 20150057262
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: October 30, 2014
    Publication date: February 26, 2015
    Inventors: Patrick Y.S. Lam, Charles G. Clark, James R. Corte, William R. Ewing, Paul J. Gilligan, Yoon Jeon, Wu Yang, Leon M. Smith, II, Yufeng Wang
  • Publication number: 20150051392
    Abstract: The present invention relates to compounds that are useful as metal ligands and which contain a moiety capable of binding to a biological entity and methods of making these compounds. These compounds are of interest as they can be bound to a biological entity and then coordinated with a suitable metallic radionuclide. The coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging.
    Type: Application
    Filed: December 6, 2012
    Publication date: February 19, 2015
    Applicant: The University of Melbourne
    Inventors: Paul Donnelly, Brett Paterson
  • Patent number: 8901115
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: December 2, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Patrick Y. S. Lam, Charles G. Clark, James R. Corte, William R. Ewing, Paul J. Gilligan, Yoon Jeon, Wu Yang, Leon M. Smith, II, Yufeng Wang
  • Patent number: 8865890
    Abstract: A device is presented having reversibly changeable and optically readable optical properties. The device comprises a substrate having an electrically conductive surface and carrying a redox-active layer structure. The redox-active layer structure may be a monolayer or a multi-layer structure and is configured to have at least one predetermined electronic property including at least one of electrodensity and oxidation state. The electronic property of the layer structure defines an optical property of the structure thereby determining an optical response of the structure to certain incident light. This at least one electronic property is changeable by subjecting the redox-active layer structure to an electric field or to a redox-active material. The device thus enables effecting a change in said electronic property that results in a detectable change in the optical response of the layer structure.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: October 21, 2014
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Milko E. Van Der Boom, Atindra D. Shukla, David Rosenblatt, Tarkeshwar Guptar
  • Publication number: 20140249137
    Abstract: The present invention relates to compounds useful as inhibitors of treating tuberculosis.
    Type: Application
    Filed: October 31, 2013
    Publication date: September 4, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Tiansheng Wang, Brian Hanzelka, Ute Muh, Guy Bemis, Harmon J. Zuccola
  • Publication number: 20140248213
    Abstract: The present invention provides for heptamethine cyanine dyes that possess both nuclear and near-infrared imaging capabilities. These dyes can be used for imaging, targeting and detecting tumors in patients.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 4, 2014
    Applicants: CEDARS-SINAI MEDICAL CENTER, UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Leland W. K. Chung, Dongfeng Pan
  • Publication number: 20140219915
    Abstract: Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds.
    Type: Application
    Filed: July 6, 2012
    Publication date: August 7, 2014
    Applicants: AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION, THE AUSTRALIAN NATIONAL UNIVERSITY
    Inventors: Suzanne Virginia Smith, Eskender Mume, Gary James Perkins
  • Publication number: 20140212575
    Abstract: The present invention includes a novel self-assembling nanocomposite structure comprising a shape-persistent three-dimensional cage molecule. In one aspect, binding of nanoparticles to metal coordinating groups in the cage molecule allows for the self-assembly of the nanoparticles into a nanocomposite material. The present invention further includes methods of preparing such self-assembling nanocomposite structures.
    Type: Application
    Filed: September 24, 2013
    Publication date: July 31, 2014
    Inventors: Wei Zhang, Ryan McCaffrey, Wounjhang Park, Kazunori Emoto, Yinghua Jin
  • Publication number: 20140206862
    Abstract: Amine chelates capable of antioxidant capacity and amyloid disaggregation are shown which may be useful in targeting metal-based oxidative stress in neurodegenerative disorders. Pyclen, a backbone commonly investigated for contrast agent imaging, may be repurposed as an anti-oxidant chelator for disaggregating amyloid. The antioxidant capacity of pyclen is enhanced dramatically via conversion of the pyridine backbone to a pyridol with cellular studies showing superior antioxidant capacity while retaining chelation ability to protect amyloid from metal ions aggregation and also disaggregate amyloid aggregates. Another family of molecules based upon hybrid heterocyclic amine ligands is also presented.
    Type: Application
    Filed: January 16, 2014
    Publication date: July 24, 2014
    Applicant: Texas Christian University
    Inventors: Kayla Nalynn Green, Kimberly Marie Lincoln, Paulina Gonzalez
  • Publication number: 20140206683
    Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Application
    Filed: September 28, 2012
    Publication date: July 24, 2014
    Inventors: Jan Hoflack, Petra Blom
  • Publication number: 20140206861
    Abstract: Amine chelates capable of antioxidant capacity and amyloid disaggregation are shown which may be useful in targeting metal-based oxidative stress in neurodegenerative disorders. Pyclen, a backbone commonly investigated for contrast agent imaging, may be repurposed as an anti-oxidant chelator for disaggregating amyloid. The antioxidant capacity of pyclen was enhanced dramatically via conversion of the pyridine backbone to a pyridol with cellular studies showing superior antioxidant capacity while retaining chelation ability to protect amyloid from metal ions aggregation and also disaggregate amyloid aggregates.
    Type: Application
    Filed: December 13, 2013
    Publication date: July 24, 2014
    Inventors: Kayla Nalynn Green, Kimberly Marie Lincoln, Paulina Gonzalez
  • Patent number: 8772272
    Abstract: The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein a1-a2=a3-a4 represents a divalent radical selected from N—CH?CH—CH, N—CH?N—CH or CH—CH?N—CH; Z represents NH; Y represents —C3-9alkyl-, —C1-5alkyl-NR13—C1-5alkyl-, —C1-6alkyl-NH—CO— or —CO—NH—C1-6alkyl-; X1 represents —O— or —NR11—; X2 represents —C1-2alkyl-, —O—C1-2alkyl, —O— or —O—CH2—; R1 represents hydrogen or halo; R2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C1-4alkyloxycarbonyl-, Het16-carbonyl- or Ar5; R3 represents hydrogen; R4 represents hydroxy, C1-4alkyloxy-, Ar4—C1-4alkyloxy or R4 represents C1-4alkyloxy substituted with one or where possible two or more substituents selected from C1-4alkyloxy- or Het2-; R11 represents hydrogen; R12 represents hydrogen, C1-4alkyl- or C1-4alkyl-oxy-carbonyl-; R13 represents Het14-C1-4alkyl, in particular morpholinyl-C1-4alkyl; Het2 represents a heterocycle selected from m
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: July 8, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Eddy Jean Edgard Freyne, Marc Willems, Pierre Henri Storck, Virginie Sophie Poncelet, Kristof Van Emelen, Peter Jacobus Johnnes Antonius Buijnsters, Werner Constant Johan Embrechts, Timothy Pietro Suren Perera
  • Patent number: 8765727
    Abstract: The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: July 1, 2014
    Assignee: Incyte Corporation
    Inventors: Andrew Paul Combs, Richard B. Sparks, Eddy Wai Tsun Yue, Hao Feng, Michael Jason Bower, Wenyu Zhu
  • Publication number: 20140163002
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: August 6, 2012
    Publication date: June 12, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Patrick Y.S. Lam, Charles G. Clark, James R. Corte, William R. Ewing, Paul J. Gilligan, Yoon Jeon, Wu Yang, Leon M. Smith, II, Yufeng Wang
  • Patent number: 8741884
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: June 3, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, Annapurna Pendri, Guo Li, Samuel Gerritz, Weixu Zhai, Paul Michael Scola, Li-Qiang Sun, Eric Mull
  • Publication number: 20140148596
    Abstract: Crystalline COFs comprising a phthalocyanine moiety and a boron-containing multifunctional linking group joined by boronate ester bonds. A method for making crystalline COFs comprising Lewis acid catalyzed formation of boronate ester bonds between protected catechol subunits and multifunctional linkers comprising boronic acid groups. The COFs can be used in applications such as, for example, electronic devices.
    Type: Application
    Filed: April 7, 2011
    Publication date: May 29, 2014
    Applicant: CORNELL UNIVERSITY
    Inventors: William R. Dichtel, Eric L. Spitler
  • Patent number: 8722879
    Abstract: A device is presented having reversibly changeable and optically readable optical properties. The device comprises a substrate having an electrically conductive surface and carrying a redox-active layer structure. The redox-active layer structure may be a monolayer or a multi-layer structure and is configured to have at least one predetermined electronic property including at least one of electrodensity and oxidation state. The electronic property of the layer structure defines an optical property of the structure thereby determining an optical response of the structure to certain incident light. This at least one electronic property is changeable by subjecting the redox-active layer structure to an electric field or to a redox-active material. The device thus enables effecting a change in said electronic property that results in a detectable change in the optical response of the layer structure.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: May 13, 2014
    Assignee: Yeda Research & Development Company Ltd. at the Weizmann Institute of Science
    Inventors: Milko E. Van Der Boom, Atindra D. Shukla, David Rosenblatt, Tarkeshwar Gupta
  • Patent number: 8716293
    Abstract: Compound having formula I and pharmaceutically acceptable salts or solvates thereof, their pharmaceutical formulations and use as HIV inhibitors.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 6, 2014
    Assignee: Janssen R&D Ireland
    Inventors: Johannes Wilhelmus J. Thuring, Jean-Francois Bonfanti
  • Publication number: 20140091264
    Abstract: The present invention relates to organic electronic devices, in particular organic electroluminescent devices, which comprise organic cyclophanes, in particular as matrix materials for fluorescent or phosphorescent emitter compounds or as charge-transport materials, in particular electron-transport materials, and to diverse organic cyclophanes themselves.
    Type: Application
    Filed: May 16, 2012
    Publication date: April 3, 2014
    Applicant: Merck Patent GmbH
    Inventors: Junyou Pan, Niels Schulte
  • Publication number: 20140094529
    Abstract: Acyclic CB[n]-type compounds, methods of making such compounds, and uses of the compounds. For example, these compounds can be used as nanocontainers to solubilize pharmaceutical agents. Also provided are compositions and methods of using them for therapy or prophylaxis of a wide variety of conditions for which therapy or prophylaxis is desirable.
    Type: Application
    Filed: October 13, 2011
    Publication date: April 3, 2014
    Applicant: UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Lyle David Isaacs, Volker Briken, Gaya Hettiarachchi, Da Ma, Duc M. Nguyen
  • Publication number: 20140051692
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 20, 2014
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng, Timothy P. Connolly, David R. Langley, Kevin Peese, Zhongyu Wang, Michael A. Walker, John F. Kadow
  • Publication number: 20140031351
    Abstract: The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
    Type: Application
    Filed: September 13, 2013
    Publication date: January 30, 2014
    Applicant: Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Gregory R. Ott
  • Patent number: 8586584
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: November 19, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Annapurna Pendri, Zhongxing Zhang, Weixu Zhai, Guo Li, Samuel Gerritz, Paul Michael Scola, Li-Qiang Sun, Qian Zhao, Eric Mull
  • Patent number: 8513409
    Abstract: Inverted cucurbituril compounds having at least one pair of hydrogen atoms protruding into an internal molecular cavity thereof.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: August 20, 2013
    Assignees: University of Maryland, Pohang University of Science and Technology
    Inventors: Kimoon Kim, Sang-Kyu Park, Young Ho Ko, Hyunuk Kim, Youngkook Kim, Narayanan Selvapalam, Lyle David Isaacs, Simin Liu
  • Patent number: 8486928
    Abstract: The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic 16-membered macrocyclic complexes that catalytically dismutate superoxide. It also relates to methods of using these complexes to reduce the concentration or the effects of superoxide, pharmaceutical compositions comprising these compounds or their metal complexes, and methods of treating conditions associated with excessive superoxide activity.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: July 16, 2013
    Assignee: Galera Therapeutics
    Inventor: Dennis P. Riley
  • Publication number: 20130128713
    Abstract: The invention relates generally to optical data storage media, and more specifically, to holographic storage media. In one embodiment, an optical storage medium composition includes a polymer matrix. Disposed within the polymer matrix is a reactant capable of undergoing a modification that alters the refractive index of the composition upon receiving an energy transfer from an excited sensitizer. A non-linear sensitizer is also disposed within the polymer matrix, and the sensitizer includes a metal-substituted subphthalocyanine (M-sub-PC) reverse saturable absorber configured to become excited upon exposure to light beyond an intensity threshold at approximately 405 nm and configured to transfer energy to the reactant.
    Type: Application
    Filed: November 17, 2011
    Publication date: May 23, 2013
    Applicant: General Electric Company
    Inventors: Arunkumar Natarajan, Patrick Joseph McCloskey, Kwok Pong Chan, Evgenia Mikhailovna Kim, Robert Edgar Colborn, Eugene Pauling Boden
  • Publication number: 20130092903
    Abstract: A heterocyclic compound represented by Formula 1, and an organic layer including the heterocyclic compound: wherein Formula 1 is as defined in the specification. The organic light-emitting device including the heterocyclic compound has high efficiency, low driving voltage, high brightness, and long lifespan.
    Type: Application
    Filed: February 3, 2012
    Publication date: April 18, 2013
    Applicant: SAMSUNG MOBILE DISPLAY CO., LTD.
    Inventors: Bum-Woo Park, Yoon-Hyun Kwak, Sun-Young Lee
  • Patent number: 8410263
    Abstract: Disclosed herein are the methods and compositions for the improved synthesis of texaphyrin metal complexes. The improved synthesis results in high-purity compositions of texaphyrin metal complexes in which more than about 98% of the texaphyrin metal complexes in the composition have the same structure and/or the same molecular weight. Further described herein are pharmaceutical compositions comprising such high-purity compositions, and the use of such high-purity compositions in the treatment of cancer and cardiovascular diseases and disorders.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: April 2, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: Hugo Madden, Greg Hemmi, Tarak Mody
  • Publication number: 20130066068
    Abstract: The purpose of the present invention is to provide novel liquid crystalline compounds that are capable of inducing phase transition by a light stimulus and are useful in the display, optoelectronics, and photonics field. The present invention relates to the liquid crystalline compounds represented by general formula (1): wherein R1, R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, alkoxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkanoyl, alkanoyloxy, alkoxyphenyl, and N-alkylaminocarbonyl, and n is an integer.
    Type: Application
    Filed: May 10, 2011
    Publication date: March 14, 2013
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Yasuo Norikane, Yuki Hirai, Masaru Yoshida
  • Publication number: 20130060001
    Abstract: A macrocycle based on ?-diketimines, a process for preparing the inventive macrocycle, an uncharged macrocyclic dimetallic complex based on the inventive macrocycle, and a process for preparing the uncharged macrocyclic dimetallic complex, the use of the uncharged macrocyclic dimetallic complex as a polymerization catalyst in the polymerization of carbon dioxide with one or more epoxides, a process for preparing polycarbonates by reacting carbon dioxide with one or more epoxides in the presence of the inventive uncharged macrocyclic dimetallic complex, and a polycarbonate prepared by the process according to the invention.
    Type: Application
    Filed: August 30, 2012
    Publication date: March 7, 2013
    Applicant: BASF SE
    Inventors: Peter Deglmann, Anna Katharina Brym, Bernhard Rieger, Maximilian Lehenmeier, Stephan Klaus
  • Publication number: 20130039858
    Abstract: Novel fluorescent dye comprising metal oxide nanoparticles are prepared where the nanoparticles are as small as 3 nm or up to 7000 nm in diameter and where the dye is bound within the metal oxide matrix. In some embodiments the invention, novel dyes are covalently attached to the matrix and in other embodiments of the invention a dye is coordinate or ionic bound within the metal oxide matrix. A method for preparing the novel covalently bondable modified fluorescent dyes is presented. A method to prepare silica comprising nanoparticles that are 3 to 8 nm in diameter is presented. In some embodiments, the fluorescent dye comprising metal oxide nanoparticles are further decorated with functionality for use as multimodal in vitro or in vivo imaging agents. In other embodiments of the invention, the fluorescent dye comprising metal oxide nanoparticles provide therapeutic activity and incorporated therapeutic temperature monitoring.
    Type: Application
    Filed: February 24, 2011
    Publication date: February 14, 2013
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Scott Chang Brown, Amit Kumar Singh, Parvesh Sharma, Brij M. Moudgil, Stephen R. Grobmyer
  • Publication number: 20130040924
    Abstract: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a bridged polycyclic compound may be pharmaceutically active. In some embodiments, a bridged polycyclic compound may be function as a carrier for pharmaceutically active agents.
    Type: Application
    Filed: July 13, 2012
    Publication date: February 14, 2013
    Applicant: AllAccem, Inc.
    Inventor: Jeffery A. Whiteford
  • Publication number: 20130028872
    Abstract: Described are methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a cell or population of cells characteristic of the definitive endoderm, the method comprising incubating the cell or population of cells with a GSK-3 inhibitor. Also described are methods for inducing differentiation of a cell or population of cells, characteristic of the definitive endoderm, towards a hepatocyte-like cell or a population of hepatocyte-like cells, and methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a hepatocyte-like cell or a population of hepatocyte-like cells. Further described are cells obtained by the methods and uses thereof in therapy and toxicity screening.
    Type: Application
    Filed: November 26, 2010
    Publication date: January 31, 2013
    Inventors: Heather K. Bone, David Tosh, Melanie J. Welham
  • Publication number: 20120309960
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: February 10, 2011
    Publication date: December 6, 2012
    Inventors: Mimi L. Quan, Carl P. Decicco, James R. Corte, Cailan Wang
  • Publication number: 20120276001
    Abstract: A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a metal ion, such as an ion of 90Y, 111In or 177Lu; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate. A method of therapeutic treatment of a mammal involving administration of the pharmaceutical composition is also described.
    Type: Application
    Filed: May 21, 2012
    Publication date: November 1, 2012
    Applicant: Nordion (Canada) Inc
    Inventors: Zoltan Kovacs, Garry E. Kiefer, Corinne Bensimon, A. Dean Sherry, Gyula Tircso, Cara Ferreira
  • Patent number: 8299269
    Abstract: Nor-seco-type cucurbit[n]uril compounds and methylene bridged glycoluril oligomers are produced by reacting glycoluril and formaldehyde in strong organic or mineral acid at a temperature adequate to condense the reactants. These compounds are characterized by lacking —CH2— groups rendering their internal cavities more open and, for example, more responsive to guest compounds.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: October 30, 2012
    Assignee: University of Maryland
    Inventors: Lyle David Isaacs, Wei-Hao Huang
  • Publication number: 20120270141
    Abstract: To provide nitrogen-containing aromatic compounds with excellent oxygen reduction activity, metal complexes containing them, and catalysts and electrodes employing the same, the present invention provides an aromatic compound satisfying the following conditions (a) and (b): (a) It has 2 or more structures surrounded by at least 4 coordinatable nitrogen atoms (which structures may be the same or different), (b) At least one of the nitrogen atoms composing the structure is a nitrogen atom in a 6-membered nitrogen-containing heterocyclic ring.
    Type: Application
    Filed: October 29, 2010
    Publication date: October 25, 2012
    Applicants: Max Planck Gesellschaft zur Foerderung der Wissenschaften e.V., SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Nobuyoshi Koshino, Hideyuki Higashimura, Klaus Muellen, Christian von Malotki, Qi Su, Martin Baumgarten, Hassan Norouzi-Arasi, Lena Arnold, Ruili Liu
  • Publication number: 20120244081
    Abstract: The present invention relates to manganese(II) chelates. The invention also relates to said manganese(II) chelates attached to other molecules and their use as contrast agents in magnetic resonance imaging (MRI).
    Type: Application
    Filed: December 17, 2010
    Publication date: September 27, 2012
    Inventor: Andreas Meijer
  • Publication number: 20120238748
    Abstract: The present invention provides a novel compound having a phenanthroline structure represented by formula (I) or a salt thereof:
    Type: Application
    Filed: September 13, 2010
    Publication date: September 20, 2012
    Applicant: B.R.A.H.M.S GmbH
    Inventors: Mikio Hoshino, Toshisada Yano
  • Patent number: 8268381
    Abstract: A coating system and method are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two of the cyclic groups may include quaternary ammonium moieties. In some embodiments, a method may include applying a coating to a surface of a medical device. The coating may be antimicrobial. A coating may include antimicrobial bridged polycyclic compounds. In some embodiments, bridged polycyclic compounds may include quaternary ammonium compounds. In some embodiments, bridged polycyclic compounds may include guanidinium moieties. Bridged polycyclic compounds based coating systems may impart self-cleaning properties to a surface.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: September 18, 2012
    Assignee: AllAccem, Inc.
    Inventors: Jeffery A. Whiteford, William P. Freeman
  • Patent number: 8257926
    Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: September 4, 2012
    Assignee: AnaSpec Incorporated
    Inventors: Zhenjun Diwu, Jianheng Zhang, Yi Tang, Xiang Guobing
  • Publication number: 20120220566
    Abstract: The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals.
    Type: Application
    Filed: October 15, 2010
    Publication date: August 30, 2012
    Applicant: Rib-X Pharmaceuticals, Inc.
    Inventors: Erin M. Duffy, Ashoke Bhattacharjee, Hardwin O'Dowd, Marco DeVivo, Zoltan F. Kanyo, Jacek G. Martinow, Ik-Hyeon Paik, Matthew H. Scheideman, Sandra Sinishtaj, Brian T. Wimberly, Yusheng Wu
  • Publication number: 20120219495
    Abstract: Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same. The disclosed tetraaza macrocyclic compound is able to form a stable metal complex at a lower temperature and allows easy conjugation with a bioactive substance or a chemically active substance, when compared to the existing cross-bridged tetraaza macrocyclic compounds.
    Type: Application
    Filed: September 9, 2010
    Publication date: August 30, 2012
    Applicant: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Jeong Soo Yoo, Darpan Pandya
  • Patent number: 8222239
    Abstract: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a bridged polycyclic compound may be pharmaceutically active. In some embodiments, a bridged polycyclic compound may be function as a carrier for pharmaceutically active agents.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: July 17, 2012
    Assignee: AllAccem, Inc.
    Inventor: Jeffery A. Whiteford